Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Rating Consensus

Ironwood Pharmaceuticals (NASDAQ:IRWD) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 8 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. In a research note released to the investors, Cowen & Company upgrades its rating on Ironwood Pharmaceuticals (NASDAQ:IRWD).The analysts at the brokerage house have a current rating of Outperform on the shares. Earlier, the shares were rated a Market Perform by the brokerage firm. The rating by the firm was issued on April 6, 2016.

Ironwood Pharmaceuticals (NASDAQ:IRWD): 7 Analyst have given the stock of Ironwood Pharmaceuticals (NASDAQ:IRWD) a near short term price target of $12.57. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $2.7. The higher price target estimate is at $16 while the lower price estimates are fixed at $10.

Ironwood Pharmaceuticals (NASDAQ:IRWD) witnessed a decline in the market cap on Tuesday as its shares dropped 0.31% or 0.04 points. After the session commenced at $12.77, the stock reached the higher end at $12.94 while it hit a low of $12.48. With the volume soaring to 993,737 shares, the last trade was called at $12.68. The company has a 52-week high of $13.27. The company has a market cap of $1,834 million and there are 144,604,310 shares in outstanding. The 52-week low of the share price is $7.35.

Ironwood Pharmaceuticals, Inc. has dropped 1.48% in the last five trading days, however, the shares have posted positive gains of 11.03% in the last 4 weeks. Ironwood Pharmaceuticals, Inc. is up 17.3% in the last 3-month period. Year-to-Date the stock performance stands at 9.4%.

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *